Category-wise Analysis By Product, Ozempic Dominates the GLP-1 Receptor Agonist Market Ozempic (semaglutide) dominates with 32.1% share of the global market in 2025 , due to its strong efficacy in both glycemic control and weight management
Many of them have been used in weight-loss teas, pills, and powders for decades, in some cases even longer than GLP-1 medications, yet they have never caused a true breakthrough in weight-loss treatment
Oral semaglutide 2550 mg produces the largest average reduction, followed by orforglipron closely behind (57)
For example, it has been discovered that people with vitiligo are more likely to have certain TNF gene variations, indicating a genetic basis for elevated TNF- levels
Excess supplementation without proper water intake even for a short period of time may cause muscle cramps